# A Pilot Study Exploring Paraoxonase-1 Tissue Protein Expression and Circulating Levels in Bladder Cancer

**Authors:** David Parada, Alina-Iuliana Onoiu, Simona Iftimie, Jordi Camps, Francesc Riu, Antoni Castro, Jorge Joven

PMC · DOI: 10.3390/antiox15020198 · Antioxidants · 2026-02-02

## TL;DR

This study explores the expression of PON1 and MTAP in bladder cancer, suggesting their potential as markers for tumor grade and behavior.

## Contribution

The study provides the first evidence of PON1 expression in bladder cancer tissue and explores its relationship with MTAP.

## Key findings

- PON1 and MTAP expression is reduced in high-grade bladder tumors compared to low-grade tumors.
- Serum PON1 levels and activity are slightly lower in high-grade urothelial carcinoma.
- Genotype frequencies and polymorphism effects on PON1 activity are similar between patients and controls.

## Abstract

Paraoxonase-1 (PON1) is considered a liver-derived antioxidant enzyme circulating bound to high-density lipoproteins, with limited evidence of protein expression in human urothelial tissue. Its role in bladder cancer remains unexplored. Methylthioadenosine phosphorylase (MTAP), an enzyme related to tumor aggressiveness, may interact with oxidative and metabolic stress pathways relevant to tumor progression. We conducted an exploratory study integrating immunohistochemistry, serum biochemistry, and PON1 genotyping in 39 patients with low-grade (LGUC) or high-grade urothelial carcinoma (HGUC). Both PON1 and MTAP showed reduced expression in high-grade tumors, with MTAP reduction being more pronounced and consistent than that of PON1. Serum PON1 concentrations and activities were slightly reduced in HGUC compared with LGUC and controls. Genotype frequencies were similar between patients and controls, and polymorphisms influenced serum enzymatic activity similarly in both groups. Correlations between tissue and serum PON1 did not reach significance, although descriptively low tissue expression aligned with low serum levels. This study provides initial evidence of intratumoral PON1 expression in bladder cancer and suggests that combined PON1/MTAP immunohistochemical assessment may reflect tumor grade and biological behavior. Larger functional studies are needed to clarify their mechanistic and clinical relevance.

## Linked entities

- **Genes:** PON1 (paraoxonase 1) [NCBI Gene 5444], MTAP (methylthioadenosine phosphorylase) [NCBI Gene 4507]
- **Diseases:** bladder cancer (MONDO:0004986), urothelial carcinoma (MONDO:0040679)

## Full-text entities

- **Genes:** PON3 (paraoxonase 3) [NCBI Gene 5446], PON1 (paraoxonase 1) [NCBI Gene 5444] {aka ESA, MVCD5, PON}, MTAP (methylthioadenosine phosphorylase) [NCBI Gene 4507] {aka BDMF, DMSFH, DMSMFH, HEL-249, LGMBF, MSAP}, ARAP2 (ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2) [NCBI Gene 116984] {aka CENTD1, PARX}, PON2 (paraoxonase 2) [NCBI Gene 5445], CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, FGFR3 (fibroblast growth factor receptor 3) [NCBI Gene 2261] {aka ACH, CD333, CEK2, HSFGFR3EX, JTK4}
- **Diseases:** HGUC (MESH:D008228), liver impairment (MESH:D017093), chronic (MESH:D002908), infectious diseases (MESH:D003141), Bladder Cancer (MESH:D001749), urothelial and other cancers (MESH:D014523), carcinogenic (MESH:D011230), cardiovascular disorders (MESH:D002318), MUSC (MESH:D000093284), toxicity (MESH:D064420), injury to (MESH:D014947), inflammation (MESH:D007249), hepatic disorders (MESH:D008107), alcohol abuse (MESH:D000437), LGUC (MESH:D015451), diabetes mellitus (MESH:D003920), Tumor (MESH:D009369), carcinoma in situ (MESH:D002278), psychiatric disease (MESH:D001523), renal insufficiency (MESH:D051437)
- **Chemicals:** sodium carbonate (MESH:C005686), lipids (MESH:D008055), alcohol (MESH:D000438), eosin (MESH:D004801), PBS (MESH:D007854), reactive oxygen species (MESH:D017382), H2SO4 (MESH:C033158), Formalin (MESH:D005557), H&amp;E (MESH:D006371), organophosphate (MESH:D010755), 5-thiobutyl butyrolactone (-), hematoxylin (MESH:D006416), Paraoxon (MESH:D010261), water (MESH:D014867), isopropanol (MESH:D019840), 5,5'-dithio-bis-2-nitrobenzoic acid (MESH:D004228), CaCl2 (MESH:D002122), glycine (MESH:D005998), methionine (MESH:D008715), paraffin (MESH:D010232), EDTA (MESH:D004492), 3,3',5,5'-tetramethylbenzidine (MESH:C021758), lipid peroxides (MESH:D008054), phenylacetate (MESH:C025136)
- **Species:** Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]
- **Mutations:** rs854560, Q192R, C in 0
- **Cell lines:** PPC — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_4778)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938387/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938387/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938387/full.md

---
Source: https://tomesphere.com/paper/PMC12938387